Medline (MDLN) is back on investor radars after a quiet stretch, with the stock hovering around 29 dollars despite sizable annual revenue and steady profitability that invite a closer look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback